Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has swung higher to the tune of almost 8%. Interestingly, Friday’s afterhours ...

Inside Gilead Sciences, colleagues often describe Varun Sharma as the strategist who can map a launch plan end to end, and ...

Privately-held dermatology specialist LEO Pharma today revealed robust growth and significantly improved profitability, ...

What is MFN in pharma? President Trump’s executive order on drug pricing states that the United States should be treated as a ...

H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences (ASMB) with a Buy rating and $50 price target The firm sees ...

Sophisticated new technology allows scammers to generate fake video and audio of a real person speaking to make them appear ...

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs?

Health Minister Aaron Motsoaledi told Bhekisisa 's TV show, Health Beat, in July , that he "would strongly consider" a ministerial advisory committee (MAC), like the one we had during the COVID ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer care across a wide range of tumor types and disease ...